Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients
- PMID: 20688881
- DOI: 10.1677/ERC-10-0059
Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients
Abstract
Androgen receptors (ARs) are probably of importance during all phases of prostate cancer (PC) growth, but their role in bone metastases is largely unexplored. Bone metastases were therefore collected from hormone-naive (n=11), short-term castrated (n=7) and castration-resistant PC (CRPC, n=44) patients by biopsy (n=4) or at surgery to alleviate symptoms from metastases complications (metastasis surgery, n=58), and immunostained for nuclear ARs, Ki67, active caspase-3, prostate-specific antigen (PSA) and chromogranin A, and results were related to serum PSA, treatments and outcome. Nuclear AR immunostaining was decreased and apoptosis was increased, but cell proliferation remained largely unaffected in metastases within a few days after surgical castration. In CRPC patients, nuclear AR staining of metastases was increased when compared to short-term castrated patients. The nuclear AR staining score was related to tumour cell proliferation, but it was not associated with other downstream effects of AR activation such as apoptosis and PSA staining, and it was only marginally related to the presence of neuroendocrine tumour cells. Serum PSA at metastasis surgery, although related to outcome, was not associated with AR staining, markers of metastasis growth or PSA staining in metastases. High nuclear AR immunostaining was associated with a particularly poor prognosis after metastasis surgery in CRPC patients, suggesting that such men may benefit from the potent AR blockers now tested in clinical trials.
Similar articles
-
Cellular changes in prostate cancer cells induced by intermittent androgen suppression.Eur Urol. 2007 Sep;52(3):725-32. doi: 10.1016/j.eururo.2006.11.043. Epub 2006 Nov 28. Eur Urol. 2007. PMID: 17141945 Clinical Trial.
-
Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.J Bone Miner Res. 2009 Jul;24(7):1180-93. doi: 10.1359/jbmr.090219. J Bone Miner Res. 2009. PMID: 19257827
-
Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.BJU Int. 2006 Jan;97(1):170-8. doi: 10.1111/j.1464-410X.2006.05857.x. BJU Int. 2006. PMID: 16336351
-
Androgen receptor action in hormone-dependent and recurrent prostate cancer.J Cell Biochem. 2006 Oct 1;99(2):362-72. doi: 10.1002/jcb.20811. J Cell Biochem. 2006. PMID: 16619264 Review.
-
Prognostic value of serum markers for prostate cancer.Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. doi: 10.1080/03008880510030941. Scand J Urol Nephrol Suppl. 2005. PMID: 16019759 Review.
Cited by
-
Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.PLoS One. 2013 Nov 7;8(11):e77407. doi: 10.1371/journal.pone.0077407. eCollection 2013. PLoS One. 2013. PMID: 24244276 Free PMC article. Clinical Trial.
-
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review.Biomolecules. 2021 Mar 25;11(4):492. doi: 10.3390/biom11040492. Biomolecules. 2021. PMID: 33805919 Free PMC article. Review.
-
Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy.Cancers (Basel). 2022 Oct 23;14(21):5195. doi: 10.3390/cancers14215195. Cancers (Basel). 2022. PMID: 36358614 Free PMC article.
-
Compressed Prostate Cancer Cells Decrease Osteoclast Activity While Enhancing Osteoblast Activity In Vitro.Int J Mol Sci. 2023 Jan 1;24(1):759. doi: 10.3390/ijms24010759. Int J Mol Sci. 2023. PMID: 36614201 Free PMC article.
-
A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression.Eur Urol Open Sci. 2022 Dec 26;48:44-53. doi: 10.1016/j.euros.2022.12.004. eCollection 2023 Feb. Eur Urol Open Sci. 2022. PMID: 36743403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous